Anzeige
Mehr »
Login
Donnerstag, 30.05.2024 Börsentäglich über 12.000 News von 688 internationalen Medien
Die neuen Aktien-Stars der nächsten Rallye-Stufe im Uransektor
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CVW2 | ISIN: US1374041093 | Ticker-Symbol:
NASDAQ
29.05.24
21:57 Uhr
8,830 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CANDEL THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
CANDEL THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur CANDEL THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiCandel (CADL) Stock Skyrockets 431% Year to Date: Here's Why1
FrCandel (CADL) Reports Upbeat Data From Lung Cancer Study6
FrCandel jumps on positive mid-stage trial data for lung cancer treatment5
FrCandel Therapeutics' CAN-2409 Enhances NSCLC Survival In Phase 2 Trial; Stock Surges6
23.05.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting75Median overall survival of 20.6 months was observed following two administrations of CAN-2409 + valacyclovir in NSCLC patients with progressive disease despite immune checkpoint inhibitor therapy...
► Artikel lesen
23.05.Candel Therapeutics, Inc. - 8-K, Current Report2
22.05.Looking Into Candel Therapeutics' Recent Short Interest4
20.05.Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting3
14.05.Candel Therapeutics GAAP EPS of -$0.283
14.05.Candel Therapeutics, Inc. - 10-Q, Quarterly Report3
14.05.Candel Therapeutics, Inc. - 8-K, Current Report1
14.05.Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights71Announced positive survival data from ongoing randomized phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancerPhase 2 topline overall survival data for CAN-2409 in non-small...
► Artikel lesen
25.04.Candel Therapeutics, Inc. - 8-K, Current Report9
25.04.Candel Therapeutics, Inc. - 10-K/A, Annual Report3
19.04.How Is The Market Feeling About Candel Therapeutics?2
12.04.Candel wins FDA orphan drug designation for pancreatic cancer drug4
12.04.Candel (CADL) Up as Pancreatic Cancer Drug Gets Orphan Drug Tag1
12.04.LPCN, ADIL and CADL among pre-market losers3
11.04.What's Going On With Candel Therapeutics Stock?5
11.04.Candel Therapeutics jumps on orphan drug tag for lead cancer therapy3
Seite:  Weiter >>
64 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1